Shares of Omnicell Inc. (OMCL) surged 5.13% on Monday, following the company's impressive fourth quarter 2024 earnings results that topped expectations. The healthcare technology company reported adjusted earnings per share of $0.60, surging 81.8% year-over-year and beating the consensus estimate by 5.2%.
Revenues for the quarter climbed 18.6% to $306.9 million, also exceeding analysts' projections by 3.3%. The company's gross margin expanded significantly by 547 basis points to 46.2%, driven by an improved macroeconomic environment and timing of product implementations.
For full-year 2025, Omnicell provided an upbeat outlook, forecasting revenues between $1.105 billion and $1.155 billion, with adjusted EPS in the range of $1.65 to $1.85. The company's strong performance and positive guidance fueled investor confidence, resulting in the substantial intraday stock surge.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。